{"id":10611,"date":"2024-02-07T07:38:00","date_gmt":"2024-02-07T06:38:00","guid":{"rendered":"https:\/\/bio-pat.org\/?p=10611"},"modified":"2024-02-11T07:48:32","modified_gmt":"2024-02-11T06:48:32","slug":"fyonibio-collaborates-with-biolamina-and-alder-therapeutics","status":"publish","type":"post","link":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics","title":{"rendered":"FyoniBio collaborates with BioLamina and Alder Therapeutics"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\" style=\"font-size:18px\"><strong>FyoniBio collaborates with BioLamina and Alder Therapeutics<\/strong><\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\">FyoniBio, a contract development organization (CDO) specializing in customized cell line and process development has partnered with BioLamina, a biotech company renowned for its expertise in extracellular laminin-based cell biology and development of laminins as tools for cell culture, and Alder Therapeutics, a virtual preclinical allogeneic stem cell therapy development company. The consortium will advance the development of laminins for clinical applications.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\">As part of the grant-funded consortium, BioLamina and FyoniBio have executed a Master Service Agreement under which FyoniBio will use its long-standing expertise in cell line development in a variety of different mammalian cell systems, including human cell lines, to develop production clones for a couple of BioLamina\u2019s full-length human recombinant laminins.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\">\u201cFyoniBio is honored to collaborate with BioLamina and Alder Therapeutics in this transformative project. The synergy between FyoniBio\u2019s advanced human cell line development capabilities, BioLamina\u2019s legacy and significant impact on cell culture standardization and quality by their laminins as substrates, and Alder\u2019s innovative cell therapy development platform will make for a fruitful collaboration. This is the latest step in our collective commitment to help advancing cell therapies\u201d, commented Dr. Lars St\u00f6ckl, Managing Director at FyoniBio. \u201c<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\">\u201cThe collaboration between BioLamina, FyoniBio and Alder Therapeutics, supported by the secured grant funding, will enable us to combine the specific expertise of all three parties, which we expect will result in a further pushing of the boundaries of cell therapy\u201d, says Veronica Byfield Sk\u00f6ld, CEO of BioLamina<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\">\u201cBoth FyoniBio and BioLamina are renowned for their complex protein production expertise, so partnering with them is a fantastic opportunity,\u201d commented Dr. Kristian Tryggvason, CEO at Alder therapeutics. \u201cThis collaboration will provide us with additional support for our manufacturing process, so we can help treat the Retinitis Pigmentosa patients\u201d, commented Dr. Kristian Tryggvason, CEO at Alder therapeutics.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\">For more information about FyoniBio, please visit fyonibio.com. For more information about BioLamina, please visit biolamina.com. To find out more about Alder Therapeutics, please visit aldertx.com.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><strong>About FyoniBio GmbH<\/strong><br>FyoniBio\u2019s ISO-9001 certified service portfolio covers the development chain from cell line development, process development and in-depth analytical characterization, including bioassays and clinical sample monitoring under GCLP. FyoniBio\u2019s expertise builds on the long-standing experience of their scientists who have developed various cell lines and processes which entered late-stage clinical trials. FyoniBio`s customized approaches enable rapid, high-titer cell line development in various mammalian host cell lines specialized in meeting individual product requirements. Besides the CHOnamite\u00ae platform, FyoniBio provides the human GEX\u00ae platform, which is particularly suited for recombinant proteins with complex glycan structures. Furthermore, FyoniBio is highly skilled in mass spectrometry based in-depth analytical characterization of biopharmaceuticals and offers the whole package of clinical sample analysis from assay establishment, validation and measurement of clinical samples under GCLP.<br>All services are established according to the internal quality management system to assure compliance with international ISO standard and meeting international GMP standards.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><strong>About BioLamina AB<\/strong><br>BioLamina is a Swedish biotechnology company founded in 2009, built on a strong scientific foundation in cell biology and with a legacy in extracellular matrix biology. BioLamina develops, manufactures and commercializes human recombinant laminin substrates to better reflect a biorelevant environment for cultured cells in order to maintain control, gain protocol precision and create safe cells for therapy.<br>With its expansive portfolio of cell culture matrices, BioLamina has established itself as a key player in advancing cell therapy worldwide, recognized for its premium products, deep scientific competence and state-of-the-art service.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><strong>About Alder Therapeutics<\/strong><br>Alder Therapeutics is a biotechnology company on a mission to cure the incurable by harnessing the potential of pluripotent stem cell-developed therapies. Through our unique cell therapy development philosophy, we overcome the challenges of traditional development approaches, embedding risk reduction and commercial-mindedness at the core of cell therapy programs.<br>We have two promising allogenic stem cell therapies in the pipeline, both with pre-clinical proof of concept data. Our flagship program is a retinal cell therapy aiming to revolutionize treatment of Retinitis Pigmentosa.<\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><strong>FyoniBio Contact:<\/strong><br>Dr. Ulrike Scheffler; Senior Director Business Development<br>E-mail:\u00a0<a href=\"mailto:contact@fyonibio.com\">contact@fyonibio.com<\/a><br>Phone: +49 (0) 17619489825<br><a href=\"http:\/\/www.fyonibio.com\/\">www.fyonibio.com<\/a><\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><strong>BioLamina Contact:<\/strong><br>Veronica Byfield Sk\u00f6ld, CEO<br>E-mail:\u00a0<a href=\"mailto:veronica.skold@biolamina.com\">veronica.skold@biolamina.com<\/a><br><a href=\"http:\/\/www.biolamina.com\/\">www.biolamina.com<\/a><\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><strong>Alder Therapeutics Contact:<\/strong><br>Naomi Day, Senior Account manager<br>E-mail:\u00a0<a href=\"mailto:nday@biostratamarketing.com\">nday@biostratamarketing.com<\/a><br><a href=\"http:\/\/www.aldertx.com\/\">www.aldertx.com<\/a><\/p>\n\n\n\n<p class=\"has-normal-font-size wp-block-paragraph\"><a href=\"https:\/\/www.fyonibio.com\/wp-content\/uploads\/2024\/02\/Press-Release-BioLamina_Alder_FB_final_02-2024.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Read press release<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Source:\u00a0<a href=\"https:\/\/www.fyonibio.com\/2024\/02\/05\/fyonibio-gets-cir\/\" target=\"_blank\" rel=\"noreferrer noopener\">FyoniBio GmbH<\/a>\u00a0(a\u00a0<a href=\"https:\/\/bio-pat.org\/\" target=\"_blank\" rel=\"noreferrer noopener\">Bio-PAT<\/a>\u00a0member)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FyoniBio collaborates with BioLamina and Alder Therapeutics FyoniBio, a contract development organization (CDO) specializing in customized cell line and process development has partnered with BioLamina, a biotech company renowned for [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":10613,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":[],"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueState":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_VenueShowMap":false,"_VenueShowMapLink":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-allgemein"],"featured_image_src":{"landsacpe":["https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder-1140x445.jpg",1140,445,true],"list":["https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder-463x348.jpg",463,348,true],"medium":["https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder-300x200.jpg",300,200,true],"full":["https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg",1200,800,false]},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FyoniBio collaborates with BioLamina and Alder Therapeutics - Bio-PAT<\/title>\n<meta name=\"description\" content=\"FyoniBio, a CDO specializing in customized cell line and process development collaborates with BioLamina and Alder Therapeutics.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FyoniBio collaborates with BioLamina and Alder Therapeutics - Bio-PAT\" \/>\n<meta property=\"og:description\" content=\"FyoniBio, a CDO specializing in customized cell line and process development collaborates with BioLamina and Alder Therapeutics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"Bio-PAT\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-07T06:38:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-11T06:48:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neu.bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anika Bockisch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anika Bockisch\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\"},\"author\":{\"name\":\"Anika Bockisch\",\"@id\":\"https:\\\/\\\/neu.bio-pat.org\\\/en#\\\/schema\\\/person\\\/974960a088fd4a44cf19ec01374eb82d\"},\"headline\":\"FyoniBio collaborates with BioLamina and Alder Therapeutics\",\"datePublished\":\"2024-02-07T06:38:00+00:00\",\"dateModified\":\"2024-02-11T06:48:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\"},\"wordCount\":728,\"image\":{\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bio-pat.org\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/FyoniBio-Bio-Lamina-Alder.jpg\",\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\",\"url\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\",\"name\":\"FyoniBio collaborates with BioLamina and Alder Therapeutics - Bio-PAT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neu.bio-pat.org\\\/en#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bio-pat.org\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/FyoniBio-Bio-Lamina-Alder.jpg\",\"datePublished\":\"2024-02-07T06:38:00+00:00\",\"dateModified\":\"2024-02-11T06:48:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/neu.bio-pat.org\\\/en#\\\/schema\\\/person\\\/974960a088fd4a44cf19ec01374eb82d\"},\"description\":\"FyoniBio, a CDO specializing in customized cell line and process development collaborates with BioLamina and Alder Therapeutics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage\",\"url\":\"https:\\\/\\\/bio-pat.org\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/FyoniBio-Bio-Lamina-Alder.jpg\",\"contentUrl\":\"https:\\\/\\\/bio-pat.org\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/FyoniBio-Bio-Lamina-Alder.jpg\",\"width\":1200,\"height\":800,\"caption\":\"FyoniBio collaborates with BioLamina and Alder Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/bio-pat.org\\\/en\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FyoniBio collaborates with BioLamina and Alder Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neu.bio-pat.org\\\/en#website\",\"url\":\"https:\\\/\\\/neu.bio-pat.org\\\/en\",\"name\":\"Bio-PAT\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neu.bio-pat.org\\\/en?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neu.bio-pat.org\\\/en#\\\/schema\\\/person\\\/974960a088fd4a44cf19ec01374eb82d\",\"name\":\"Anika Bockisch\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d8bc886b674acebf63d284f8b3d6096890924641c5b2503c2c589662d7d78355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d8bc886b674acebf63d284f8b3d6096890924641c5b2503c2c589662d7d78355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d8bc886b674acebf63d284f8b3d6096890924641c5b2503c2c589662d7d78355?s=96&d=mm&r=g\",\"caption\":\"Anika Bockisch\"},\"url\":\"https:\\\/\\\/bio-pat.org\\\/en\\\/author\\\/anika\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FyoniBio collaborates with BioLamina and Alder Therapeutics - Bio-PAT","description":"FyoniBio, a CDO specializing in customized cell line and process development collaborates with BioLamina and Alder Therapeutics.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics","og_locale":"en_US","og_type":"article","og_title":"FyoniBio collaborates with BioLamina and Alder Therapeutics - Bio-PAT","og_description":"FyoniBio, a CDO specializing in customized cell line and process development collaborates with BioLamina and Alder Therapeutics.","og_url":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics","og_site_name":"Bio-PAT","article_published_time":"2024-02-07T06:38:00+00:00","article_modified_time":"2024-02-11T06:48:32+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/neu.bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg","type":"image\/jpeg"}],"author":"Anika Bockisch","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Anika Bockisch","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#article","isPartOf":{"@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics"},"author":{"name":"Anika Bockisch","@id":"https:\/\/neu.bio-pat.org\/en#\/schema\/person\/974960a088fd4a44cf19ec01374eb82d"},"headline":"FyoniBio collaborates with BioLamina and Alder Therapeutics","datePublished":"2024-02-07T06:38:00+00:00","dateModified":"2024-02-11T06:48:32+00:00","mainEntityOfPage":{"@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics"},"wordCount":728,"image":{"@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg","articleSection":["Allgemein"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics","url":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics","name":"FyoniBio collaborates with BioLamina and Alder Therapeutics - Bio-PAT","isPartOf":{"@id":"https:\/\/neu.bio-pat.org\/en#website"},"primaryImageOfPage":{"@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage"},"image":{"@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg","datePublished":"2024-02-07T06:38:00+00:00","dateModified":"2024-02-11T06:48:32+00:00","author":{"@id":"https:\/\/neu.bio-pat.org\/en#\/schema\/person\/974960a088fd4a44cf19ec01374eb82d"},"description":"FyoniBio, a CDO specializing in customized cell line and process development collaborates with BioLamina and Alder Therapeutics.","breadcrumb":{"@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#primaryimage","url":"https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg","contentUrl":"https:\/\/bio-pat.org\/wp-content\/uploads\/2024\/02\/FyoniBio-Bio-Lamina-Alder.jpg","width":1200,"height":800,"caption":"FyoniBio collaborates with BioLamina and Alder Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/bio-pat.org\/en\/fyonibio-collaborates-with-biolamina-and-alder-therapeutics#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/bio-pat.org\/en"},{"@type":"ListItem","position":2,"name":"FyoniBio collaborates with BioLamina and Alder Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/neu.bio-pat.org\/en#website","url":"https:\/\/neu.bio-pat.org\/en","name":"Bio-PAT","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neu.bio-pat.org\/en?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/neu.bio-pat.org\/en#\/schema\/person\/974960a088fd4a44cf19ec01374eb82d","name":"Anika Bockisch","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d8bc886b674acebf63d284f8b3d6096890924641c5b2503c2c589662d7d78355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d8bc886b674acebf63d284f8b3d6096890924641c5b2503c2c589662d7d78355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d8bc886b674acebf63d284f8b3d6096890924641c5b2503c2c589662d7d78355?s=96&d=mm&r=g","caption":"Anika Bockisch"},"url":"https:\/\/bio-pat.org\/en\/author\/anika"}]}},"_links":{"self":[{"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/posts\/10611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/comments?post=10611"}],"version-history":[{"count":1,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/posts\/10611\/revisions"}],"predecessor-version":[{"id":10614,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/posts\/10611\/revisions\/10614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/media\/10613"}],"wp:attachment":[{"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/media?parent=10611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/categories?post=10611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bio-pat.org\/en\/wp-json\/wp\/v2\/tags?post=10611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}